Teewinot Capital Advisers’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Teewinot Capital Advisers’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,000,000	Closed	-$690K	–	44
2020 Q4	$690K	Hold	1,000,000	–	–	0.22%	24
2020 Q3	$2.25M	Hold	1,000,000	–	–	0.95%	16
2020 Q2	$3.58M	Hold	1,000,000	–	–	1.8%	13
2020 Q1	$3.8M	Hold	1,000,000	–	–	2.89%	10
2019 Q4	$3.01M	Buy	+1,000,000	New	+$2.6M	0.89%	13

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Teewinot Capital Advisers's BMY.RT Position: Q1 2021 in Review

Teewinot Capital Advisers sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 1,000,000 shares — an estimated $690K sold.

Teewinot Capital Advisers first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $3.8M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Teewinot Capital Advisers reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Teewinot Capital Advisers sold 1,000,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $690K.
Teewinot Capital Advisers first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Teewinot Capital Advisers's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $3.8M in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Teewinot Capital Advisers's 13F filing for Q1 2021, filed 17 May 2021.